Establishment of an at-line nanofractionation-based screening platform by coupling HPLC-MS/MS with high-throughput fluorescence polarization bioassay for natural SARS-CoV-2 fusion inhibitors

•A fluorescence polarization-based at-line nanofractionation platform was developed.•Semi-HPLC and orthogonal separation were exploited to identify co-eluted compounds.•28 potential SARS-CoV-2 fusion inhibitors were identified.•4 potential dual-target inhibitors against influenza and SARS-CoV-2 were...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Chromatography A 2024-08, Vol.1728, p.464986, Article 464986
Main Authors: Yuan, Jiaming, Wang, Jincai, Chen, Zhixu, Chang, Yuexiang, Chen, Litong, Gao, Zhizeng, Crommen, Jacques, Zhang, Tingting, Jiang, Zhengjin
Format: Article
Language:English
Subjects:
At-line nanofractionation
High-throughput fluorescence polarization bioassay
Liquid chromatography-mass spectrometry
Natural products
SARS-CoV-2 fusion inhibitors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•A fluorescence polarization-based at-line nanofractionation platform was developed.•Semi-HPLC and orthogonal separation were exploited to identify co-eluted compounds.•28 potential SARS-CoV-2 fusion inhibitors were identified.•4 potential dual-target inhibitors against influenza and SARS-CoV-2 were found. In this study, a novel at-line nanofractionation platform was established for screening SARS-CoV-2 fusion inhibitors from natural products for the first time by combining HPLC-MS/MS with high-throughput fluorescence polarization (FP) bioassay. A time-course FP bioassay in 384 well-plates was conducted in parallel with MS/MS to simultaneously obtain chemical and biological information of potential fusion inhibitors in Lonicerae Japonicae Flos (LJF) and Lianhua Qingwen capsules (LHQW). Semi-preparative liquid chromatography and orthogonal HPLC separation were employed to enrich and better identify the co-eluted components. After comprehensive evaluation and validation, 28 potential SARS-CoV-2 fusion inhibitors were screened out and identified. Several compounds at low micromolar activity were validated by in vitro inhibitory assay, molecular docking, cytotoxicity test, and pseudovirus assay. Moreover, four potential dual-target inhibitors against influenza and COVID-19 were discovered from LJF using this method, offering novel insights for the development of future pharmaceuticals targeting epidemic respiratory diseases.
ISSN:0021-9673
DOI:10.1016/j.chroma.2024.464986